<DOC>
	<DOCNO>NCT02633813</DOCNO>
	<brief_summary>The current study randomize , double blind , placebo-controlled , prospective , multicenter , comparative therapeutic equivalence study . The study duration patient 6 week : Following visit detail . V1-Baseline Randomization Visit ( Day 1 ) . V2- End therapy visit ( end week 2 + 2 day ) . V3- Follow visit ( end week 4 + 2 day ) . V4 - Test cure visit ( end week 6 + 4 day ) .</brief_summary>
	<brief_title>BE Study Naftifine HCL</brief_title>
	<detailed_description />
	<mesh_term>Tinea</mesh_term>
	<mesh_term>Tinea Pedis</mesh_term>
	<mesh_term>Naftifine</mesh_term>
	<criteria>1 . Healthy male female age equal 18 year 2 . Clinical diagnosis tinea pedis lesion localize interdigital space predominantly interdigital , may extend area foot ( noninterdigital lesion hyperkeratotic , i.e. , characteristic tinea pedis moccasin ) , provisionally confirm baseline positive potassium hydroxide ( KOH ) wet mount preparation ( i.e. , skin scraping target site place microscope slide drop 10 % KOH , microscopic examination reveals segment fungal hypha ) 3 . The sum clinical sign symptom score target lesion least 4 , include minimum score least 2 erythema AND minimum score 2 either scale pruritus ( scale 03 , 2 indicates moderate severity ) 1 . Pregnant lactate plan become pregnant study period 2 . Use antipruritic , include antihistamine , within 72 hour prior entry study 3 . Use topical corticosteroid , antibiotic antifungal therapy within 2 week prior entry study 4 . Use systemic ( e.g. , oral injectable ) corticosteroid , antibiotic antifungal therapy within 1 month prior entry study 5 . Use oral terbinafine itraconazole within 2 month prior entry study 6 . Use immunosuppressive medication radiation therapy within 3 month prior entry study . 7 . Confluent , diffuse moccasintype tinea pedis entire plantar surface . 8 . Presence infection foot disease process might confound treatment evaluation 9 . History dermatophyte infection unresponsive systemic topical antifungal drug 10 . Known hypersensitivity Naftifine Hydrochloride component formulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Tinea pedis</keyword>
	<keyword>Naftin</keyword>
</DOC>